Wednesday, May 18, 2011

Sarcoma Drug Clinical Trial Seeking Patients

Ziopharm Oncology, Inc. has begun a Phase III clinical trial on Palifosfamide, a promising drug for the treatment of metastatic soft tissue sarcoma. This is a multicenter, international randomized, double-blinded, placebo controlled study of doxorubicin plus palifosfamide compared to doxorubicin plus placebo. Patients must be over 18 years old, have documented sarcoma and have not received prior treatment. Certain subtypes of sarcoma are also not eligible, e.g. alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor / carcinosarcoma and osteosarcoma.

Patients will receive either palifosfamide or a placebo on days 1, 2, and 3 of each cycle of doxorubicin. A maximum of six cycles can be administered.

The trial will be conducted in over 400 centers throughout the world to about 420 patients. Ziopharm hopes to have all patients enrolled by the end of 2011.

For more information on the trial, eligibility requirements and locations please visit: .

No comments: